A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...

Alumis shares rose after the company signed a licensing agreement, worth $40 million in the short-term, with Tokyo-based Kaken Pharmaceutical. The stock climbed 17.9% to $4.45 on Tuesday, recovering ...

Stocks Leading in March. In this article, we are going to take a look at where Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ...

Proficio Capital Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...

Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a ...

Trump announces imminent tariffs on automobiles, with exemptions, and 25% secondary tariff on countries purchasing oil, gas ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

MIRA Pharmaceuticals (MIRA) announced that it has signed a binding letter of intent or LOI to acquire SKNY Pharmaceuticals… The transaction ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...